Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun 15;16(12):3226-31.
doi: 10.1158/1078-0432.CCR-10-0321. Epub 2010 Jun 1.

Complement factor H autoantibodies are associated with early stage NSCLC

Nita Amornsiripanitch  1 , Shaolin Hong, Michael J Campa, Michael M Frank, Elizabeth B Gottlin, Edward F Patz Jr
Affiliations

Complement factor H autoantibodies are associated with early stage NSCLC

Nita Amornsiripanitch et al. Clin Cancer Res. .

Abstract

Purpose: To discover diagnostic biomarkers associated with early-stage non-small cell lung cancer (NSCLC), we searched for autoantibodies preferentially present in stage I patients compared with patients with advanced-stage disease. Here we describe an autoantibody against complement factor H (CFH) and this autoantibody's association with early-stage NSCLC.

Experimental design: Immunoblots were used to detect autoantibodies in the sera of stage I NSCLC patients. An autoantibody recognizing a 150 kDa protein was discovered, and the protein was identified by mass spectrometry. The association of the autoantibody with early-stage disease was suggested by the results of immunoblot analysis with sera from 28 stage I patients and 28 stage III/IV patients. This association was confirmed by protein microarray of sera from 125 NSCLC patients of all stages as well as 125 controls matched by age, gender, and smoking history.

Results: The immunoreactive protein was identified as CFH. By immunoblot analysis, anti-CFH autoantibody was found in 50% of stage I NSCLC patients and 11% of late-stage NSCLC patients (P = 0.003). By protein microarray analysis, patients with stage I NSCLC had a significantly higher incidence of anti-CFH antibody than those with late-stage NSCLC (P = 0.0051). The percentage of sera with a positive level of CFH autoantibody was 30.4% in stage I, 21.1% in stage II, 12.5% in stage III, 7.4% in stage IV, and 8.0% in the control group.

Conclusions: These findings suggest that in patients with NSCLC, CFH autoantibody is a molecular marker associated with early-stage disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Immunoblots probed with NSCLC patient sera. A, Pooled serum blot: Ten individual serum samples from patients with stage I NSCLC were used to probe a blot containing the pooled sera from 5 late stage NSCLC patients. B, CFH blot: Individual stage I, stage III/IV and normal serum samples were used to probe a blot containing purified CFH.
Fig. 2
Fig. 2
Distribution of microarray spot intensity for CFH autoantibody shown by stage (stage I [n=46], stage II [n=19], stage III [n=32], stage IV [n=27]). The horizontal line represents the median spot intensity for each stage.
Fig. 3
Fig. 3
Fraction of sera in all stages of cancer (cancer) vs. control and by stage with a positive level of CFH autoantibody in the microarray. For definition of positivity, the cutoff point is defined as 2SD greater than the mean spot intensity for CFH autoantibody of the control group (0.705), or as the optimal cutoff value determined from ROC analysis (0.600).
Fig. 4
Fig. 4
Fraction of sera in early (I/II) and late (III/IV) stage NSCLC with a positive level of CFH autoantibody in the microarray. The cutoff points for positivity are as described in the legend to Fig. 3. For comparison, the proportion of sera in each group defined as positive from a visual assessment of immunoblots is shown.
See this image and copyright information in PMC

References

    1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14. - PubMed
    1. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:694–705. - PubMed
    1. Reuschenbach M, Doeberitz M von Knebel, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 2009;58:1535–44. - PMC - PubMed
    1. Hoagland LF, 4th, Campa MJ, Gottlin EB, Herndon JE, 2nd, Patz EF., Jr Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer. 2007;110:2260–8. - PubMed
    1. Sayegh R, Awwad JT, Maxwell C, Lessey B, Isaacson K. Alpha 2-macroglobulin production by the human endometrium. J Clin Endocrinol Metab. 1995;80:1021–6. - PubMed

Publication types